KIDS Stock Cash Flow Statements

OrthoPediatrics Corp Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

OrthoPediatrics Corp Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

operating activities
net income	-7,113,000	-10,659,000	-16,069,000	-7,919,000	-6,029,000	-7,805,000	-6,691,000	-4,591,000	-2,886,000	-6,806,000	-7,848,000	18,539,000	-333,000	-9,100,000	72,000	-2,197,000	-3,756,000	-10,379,000	-14,013,000	-4,539,000	-9,447,000	-4,945,000	-5,429,000	-2,664,000	-2,618,000	-3,020,000	-2,468,000	-1,865,000	-2,692,000	-5,000,000	-4,845,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	5,170,000	5,048,000	3,993,000	5,280,000	4,779,000	5,028,000	5,187,000	4,270,000	4,080,000	3,848,000	3,520,000	3,287,000	3,331,000	2,961,000	2,810,000	2,723,000	2,608,000	2,539,000	2,314,000	2,411,000	1,910,000	1,375,000	1,413,000	1,346,000	1,084,000	828,000	715,000	777,000	719,000	681,000	657,000
stock-based compensation	5,252,000	3,859,000	3,888,000	3,922,000	2,939,000	2,799,000	2,747,000	2,364,000	3,302,000	2,113,000	1,701,000	1,682,000	1,770,000	1,526,000	1,672,000	1,439,000	1,415,000	1,316,000	1,484,000	1,259,000	2,495,000	958,000	707,000	733,000	692,000	471,000	286,000	268,000	454,000	2,177,000	2,397,000
accretion of acquisition installment payable	36,000	62,000	62,000	62,000	256,000	281,000	280,000	280,000	431,000	381,000
deferred income taxes	49,000	196,000	-829,000	-952,000	-510,000	-2,445,000	-264,000	76,000	-401,000	-574,000	-228,000	-4,048,000	-439,000	-317,000	-238,000	-288,000	-290,000	-312,000
non-cash other	-239,000	139,000
changes in certain operating assets and liabilities:
accounts receivable - trade	-9,884,000	-1,497,000	429,000	-595,000	-5,738,000	1,155,000	3,154,000	-3,914,000	-6,962,000	-2,002,000	1,584,000	1,047,000	-6,616,000	2,000	250,000	1,065,000	-2,434,000	653,000	-62,000	-1,998,000	849,000	760,000	-694,000	373,000	-4,319,000	-1,180,000	276,000	75,000	-2,917,000	-1,235,000	83,000
inventories	-6,993,000	-1,906,000	957,000	-3,734,000	-3,789,000	-6,631,000	-4,081,000	-10,338,000	-5,881,000	-5,979,000	-2,126,000	-3,907,000	-4,155,000	-6,750,000	-1,806,000	53,000	-789,000	-2,508,000	270,000	-2,741,000	-4,503,000	-5,096,000	-3,276,000	-1,185,000	-3,020,000	-2,286,000	406,000	-1,363,000	-2,522,000	-2,202,000	-1,011,000
prepaid expenses and other current assets	18,000	-519,000	573,000	-1,731,000	550,000	-953,000	290,000	-268,000	105,000	-33,000	-1,202,000	139,000	445,000	112,000	-499,000	-244,000	-602,000	708,000	-504,000	-281,000	122,000	-56,000	223,000	-346,000	182,000	-196,000	-211,000	18,000	51,000	-283,000	-216,000
accounts payable - trade	-1,487,000	5,207,000	-2,512,000	-5,918,000	-2,412,000	6,562,000	-10,001,000	1,768,000	4,183,000	5,541,000	180,000	-5,687,000	40,000	5,258,000	389,000	-1,147,000	-1,867,000	2,058,000	2,916,000	901,000	-2,485,000	1,739,000	-1,279,000	1,746,000	-439,000	2,373,000	-1,932,000	448,000	-1,742,000	1,702,000	393,000
accrued expenses and other liabilities	5,037,000	-2,528,000	229,000	-651,000	6,008,000	-5,049,000	3,564,000	1,963,000	2,896,000	-1,571,000	1,544,000	667,000	1,823,000	-690,000	1,263,000	-1,248,000	634,000	446,000	-516,000	-429,000	1,565,000	-1,694,000	1,935,000	-346,000	1,076,000	-719,000	149,000	-263,000	1,661,000	-600,000	-255,000
other	-308,000	-1,558,000	3,366,000	-1,273,000	-2,146,000	368,000	-1,722,000	-1,264,000	-936,000	-709,000	-367,000	1,243,000	-118,000	-222,000	-91,000	-152,000	-203,000	-138,000	-61,000	26,000	-53,000	3,000	-2,000	-138,000	11,000	128,000	-16,000	362,000	-459,000	82,000	-58,000
net cash from operating activities	-10,462,000	-4,156,000	-3,987,000	-10,279,000	-6,092,000	-6,690,000	-7,543,000	-8,669,000	-4,373,000	-6,461,000	-3,341,000	-6,058,000	-8,170,000	-4,197,000	-1,235,000	-937,000	-8,976,000	-1,915,000	-157,000	-3,666,000	-7,751,000	-6,956,000	-6,926,000	-429,000	-6,943,000	-3,471,000	-2,728,000	-1,182,000	-6,640,000	-5,033,000	-3,323,000
capex	-3,445,000	-4,227,000	262,000	-1,381,000	-6,684,000	-6,460,000	-3,836,000	-2,479,000	-5,623,000	-4,940,000	523,000	-1,089,000	-5,268,000	-4,197,000	-1,635,000	-1,994,000	-1,725,000	-2,749,000	-4,056,000	-1,288,000	-1,207,000	-3,953,000	-1,280,000	-2,022,000	-3,551,000	-4,963,000	58,000	-1,144,000	-1,396,000	-2,771,000	-1,258,000
free cash flows	-13,907,000	-8,383,000	-3,725,000	-11,660,000	-12,776,000	-13,150,000	-11,379,000	-11,148,000	-9,996,000	-11,401,000	-2,818,000	-7,147,000	-13,438,000	-8,394,000	-2,870,000	-2,931,000	-10,701,000	-4,664,000	-4,213,000	-4,954,000	-8,958,000	-10,909,000	-8,206,000	-2,451,000	-10,494,000	-8,434,000	-2,670,000	-2,326,000	-8,036,000	-7,804,000	-4,581,000
investing activities
acquisition of boston o&p, net of cash acquired			0	468,000	0	-20,693,000
clinic acquisition, net of cash acquired	-100,000	-220,000
sale of short-term marketable securities			0	0	26,381,000	23,474,000	23,864,000	16,693,000	35,097,000	37,250,000	1,343,000	13,929,000	13,100,000	18,500,000
investment in private companies	0	-1,540,000
purchases of property and equipment	-3,445,000	-4,227,000	262,000	-1,381,000	-6,684,000	-6,460,000	-3,836,000	-2,479,000	-5,623,000	-4,940,000	523,000	-1,089,000	-5,268,000	-4,197,000	-1,635,000	-1,994,000	-1,725,000	-2,749,000	-4,056,000	-1,288,000	-1,207,000	-3,953,000	-1,280,000	-2,022,000	-3,551,000	-4,963,000	58,000	-1,144,000	-1,396,000	-2,771,000	-1,258,000
net cash from investing activities	-3,545,000	-5,987,000	-2,412,000	-26,768,000	19,697,000	-3,679,000	17,922,000	9,668,000	-18,223,000	32,310,000	-23,227,000	-103,919,000	-528,000	14,303,000	2,965,000	-3,044,000	-1,725,000	-5,607,000	-59,056,000	-1,288,000	-3,726,000	-5,623,000	-1,529,000	-1,736,000	-53,675,000	-4,982,000	-459,000	-1,159,000	-1,417,000	-2,930,000	-1,258,000
financing activities
proceeds from issuance of debt			0
payments on mortgage notes	-39,000	-39,000	-39,000	-42,000	-36,000	-35,000	-37,000	-36,000	-35,000	-36,000	-35,000	-35,000	-34,000	-33,000	-34,000	-33,000	-32,000	-32,000	-37,000	-27,000	-30,000	-31,000	-30,000	-29,000	-30,000	-29,000	-29,000	-28,000	-28,000	-28,000	2,000
payment of debt issuance costs			-322,000	-2,742,000
installment payment for apifix			0	0			0	0			0	0
installment payment for medtech			0	0
payments on clinic acquisition notes	-161,000	-87,000
net cash from financing activities	24,800,000	-126,000	-541,000	58,518,000	-4,269,000	-573,000	9,387,000	-15,000	-2,035,000	-36,000	-35,000	108,268,000	27,774,000	-33,000	-34,000	42,000	-32,000	30,000	-16,000	-19,679,000	70,957,000	-4,530,000	59,966,000	455,000	30,062,000	536,000	39,415,000	298,000	-28,000	-28,000	44,925,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	383,000	-79,000		684,000	-2,010,000	1,479,000		-61,000	-197,000	-138,000
net increase in cash, cash equivalents and restricted cash				22,155,000	7,326,000	-9,463,000		923,000	-24,828,000	25,675,000
cash, cash equivalents and restricted cash, beginning of year	0	45,777,000		0	0	33,027,000		0	0	10,462,000
cash, cash equivalents and restricted cash, end of period	11,176,000	35,429,000		22,155,000	7,326,000	23,564,000		923,000	-24,828,000	36,137,000
net decrease in cash, cash equivalents and restricted cash		-10,348,000
supplemental disclosures
cash paid for interest		1,269,000			537,000	223,000			0	11,000	188,000	452,000	47,000	13,000	13,000	14,000	14,000	15,000	15,000	705,000	134,000	379,000	1,997,000	1,297,000	632,000	303,000	533,000	608,000	562,000	552,000	634,000
transfer of instruments between property and equipment and inventory		-461,000			164,000	117,000
right-of-use assets obtained in exchange for lease liabilities		1,682,000
issuance of common shares in connection with boston o&p acquisition		233,000
impairment
loss on early extinguishment of debt			0
fair value adjustment of contingent consideration							-6,000	0	-2,304,000	-670,000	-480,000	-23,010,000	-5,010,000	2,570,000	-5,510,000	-1,430,000	990,000	4,150,000	1,701,000	909,000
clinic acquisitions, net of cash acquired
acquisition of medtech, net of cash acquired
acquisition of rhino assets
acquisition of mdo, net of cash acquired
acquisition of pega, net of cash acquired											0
purchase of short-term marketable securities			0				0	-4,000,000			-25,093,000
investment in private companies and purchases of licenses
payments on debt with affiliate											0
proceeds from issuance of debt with affiliate											0	0											0	0							-2,147,000
proceeds from issuance of common stock, net of issuance costs											0								0	0
proceeds from exercise of stock options							0				0	21,000			0	75,000	0	62,000	21,000	348,000	593,000	688,000	0	484,000	92,000	565,000	84,000
payment on debt			0
effect of exchange rate changes on cash											193,000	26,000	159,000	241,000	-392,000	-295,000	-126,000	155,000	-380,000	-41,000	-6,000	23,000
net increase in cash and restricted cash											-26,410,000
cash and restricted cash, beginning of period
cash and restricted cash, end of period											-26,410,000	-1,683,000	19,235,000	19,320,000	1,304,000	-4,234,000	-10,859,000	22,795,000	-59,609,000	-24,674,000	59,474,000	54,941,000
issuance of common shares for apifix installment
issuance of common shares to acquire medtech
issuance of common shares for medtech installment
issuance of common shares to acquire rhino assets
issuance of common shares to acquire mdo
debt issuance costs not yet paid
tradename impairment
payments on acquisition note				0	-390,000	-538,000
acquisition of medtech								0
trademark impairment							0				0
changes in certain current assets and liabilities:
accrued legal settlements															0	0	-5,250,000	-1,092,000
acquisition of devise ortho assets
purchases of licenses															0	-5,050,000	0	-2,858,000					-100,000	0	-151,000	-19,000	-15,000	-15,000	-21,000	-159,000	0
issuance of common shares for apifix acquisition installment											0
issuance of common shares to purchase devise ortho assets
acquisition of md ortho, net of cash acquired												0
acquisition of pega medical, net of cash acquired
acquisition of rhino
issuance of common shares to acquire md ortho												0
transfer of instruments from property and equipment to inventory										332,000	-41,000	-63,000	-76,000	-54,000	373,000	-250,000	273,000	57,000	-230,000	416,000	47,000	182,000	444,000	326,000	50,000	217,000	-699,000	467,000	290,000	304,000	53,000
acquisition installment payable											381,000	381,000	1,092,000	453,000	453,000	489,000	568,000	644,000	695,000	816,000
acquisition of telos, net of cash acquired																			0	0	0	-1,670,000
acquisition of apifix, net of cash acquired																			0	0
acquisition of band-lok intangible assets																			0	0
issuance of common shares to acquire telos																			0	0	-182,000	1,750,000
issuance of common shares to acquire apifix																			0	0
issuance of common shares to purchase band-lok intellectual property
cash and restricted cash, beginning of year												0	0	9,006,000		0	0	30,132,000		0	0	72,027,000
net increase in cash													19,235,000	10,314,000		-4,234,000				-24,674,000							36,228,000	-2,043,000	-8,085,000	-7,991,000	40,344,000
building and building improvements													0	25,000				25,000				25,000	0	0	0	25,000	0	0	0	25,000	0
furniture and fixtures													0	5,000				5,000				5,000	0	0	0	5,000	0	0	0	5,000	0
computer equipment													0	3,000				3,000				3,000	0	0	0	3,000	0	0	0	3,000	0
business software													0	3,000				3,000				3,000	0	0	0	3,000	0	0	0	3,000	0
office and other equipment													0	5,000				5,000				5,000	0	0	0	5,000	0	0	0	5,000	0
instruments													0	5,000				5,000				5,000	0	0	0	5,000	0	0	0	5,000	0
sample inventory													0	2,000				2,000				2,000	0	0	0	2,000	0	0	0	2,000	0
loss on sale of discontinued operations
net cash from operating activities - continuing operations																			-157,000	-3,666,000			-6,192,000	-648,000
net cash used by operating activities - discontinued operations
acquisition of vilex and orthex, net of cash acquired																								239,000
sale of short term investments
purchase of short term investments
payments on note with affiliate																					0	-5,000,000
issuance of common shares to acquire vilex and orthex
divestiture consideration allocated to assets held for sale
payment of term note b with revolving credit facility
issuance of common shares to acquire band-lok intellectual property
repurchases of common shares																						-187,000
net decrease in cash																		-7,337,000				-17,086,000		-1,710,000	-30,556,000	-7,917,000
purchase of notes receivable
payment of revolving credit facility with affiliate
issuance of common share sto acquire vilex and orthex
net cash from operating activities - discontinued operations																								219,000
less cash of discontinued operations, end of period																								479,000
cash of continuing operations, end of period																				-24,674,000				-2,189,000
net cash from investing activities - continuing operations
net cash from investing activities - discontinued operations
issuance of common shares to acquire band-lok
acquisition of vilex, net of cash acquired
payment of preferred stock dividends
shares surrendered by employees to pay taxes on restricted shares
cash, beginning of year																							0	0	0	60,691,000	0	0	0	42,582,000	0
accretion of redeemable convertible preferred stock																															199,000
acquisition consideration of common shares																							0	0
intellectual property license
cash, end of period																								-1,710,000	-30,556,000	52,774,000	36,228,000	-2,043,000	-8,085,000	34,591,000	40,344,000
inventories held by international distributors																									37,000	130,000	67,000	361,000	807,000	-355,000	-468,000
research and development fee obligation
payments of deferred offering costs
loss on sale of assets held for sale
proceeds from assets held for sale
research and development fee obligation termination

We provide you with 20 years of cash flow statements for OrthoPediatrics Corp stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of OrthoPediatrics Corp stock. Explore the full financial landscape of OrthoPediatrics Corp stock with our expertly curated income statements.

The information provided in this report about OrthoPediatrics Corp stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.